We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+42.53%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$3.08B
AUM Growth
+$924M
Cap. Flow
+$456M
Cap. Flow %
14.8%
Top 10 Hldgs %
38.34%
Holding
121
New
53
Increased
26
Reduced
7
Closed
25

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$122M
2
LLY icon
Eli Lilly
LLY
+$121M
3
MRVI icon
Maravai LifeSciences
MRVI
+$96M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$78.7M
5
AVTR icon
Avantor
AVTR
+$51.7M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$104M
2
MRK icon
Merck
MRK
+$94.9M
3
BIIB icon
Biogen
BIIB
+$81.3M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$67.1M
5
TMO icon
Thermo Fisher Scientific
TMO
+$52.2M

Sector Composition

Rank Sector Weight
1 Healthcare 91.07%
2 Technology 1.87%
3 Financials 0.18%
4 Industrials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXSM icon
101
Axsome Therapeutics
AXSM
$12.1B
– –
-118,000
Closed -$8.41M
BAX icon
102
Baxter International
BAX
$13.8B
– –
-620,000
Closed -$49.9M
BIIB icon
103
Biogen
BIIB
$30.7B
– –
-315,100
Closed -$81.3M
BNTX icon
104
BioNTech
BNTX
$23.5B
– –
-206,000
Closed -$14.3M
BSX icon
105
Boston Scientific
BSX
$68.4B
– –
-967,100
Closed -$37M
ELV icon
106
Elevance Health
ELV
$81.6B
– –
-176,400
Closed -$47.4M
EXEL icon
107
Exelixis
EXEL
$14.1B
– –
-769,200
Closed -$18.8M
HUM icon
108
Humana
HUM
$44B
– –
-51,500
Closed -$21.3M
IDYA icon
109
IDEAYA Biosciences
IDYA
$3.5B
– –
-1,050,800
Closed -$13.2M
IOVA icon
110
Iovance Biotherapeutics
IOVA
$2.09B
– –
-799,000
Closed -$26.3M
MRK icon
111
Merck
MRK
$321B
– –
-1,199,226
Closed -$94.9M
MRSN
112
DELISTED
Mersana Therapeutics
MRSN
– –
-30,296
Closed -$14.1M
PFE icon
113
CALL
Pfizer
PFE
$142B
– –
-6,851,000
Closed -$239M
PMVP icon
114
PMV Pharmaceuticals
PMVP
$60.3M
– –
-150,000
Closed -$5.33M
QDEL icon
115
QuidelOrtho
QDEL
$1.13B
– –
-176,879
Closed -$38.8M
TMO icon
116
Thermo Fisher Scientific
TMO
$214B
– –
-118,300
Closed -$52.2M
SGEN
117
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-531,100
Closed -$104M
CELL
118
DELISTED
PhenomeX Inc. Common Stock
CELL
– –
-25,000
Closed -$1.91M
CLVS
119
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-1,000,000
Closed -$5.83M
BMY.RT
120
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
– –
-22,684,932
Closed -$51M
ARYBU
121
DELISTED
ARYA Sciences Acquisition Corp II Unit
ARYBU
– –
-500,000
Closed -$5.41M
1 2 3 4
5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return
FPI
Financial Plan Inc Bellingham, Washington $933M AUM

Avidity Partners Management's Q4 2020 Portfolio in Review

As of Q4 2020, Avidity Partners Management held 121 positions worth $3.08B, up 43% from $2.16B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Avidity Partners Management deployed $456M of net new capital in Q4 2020, opening 53 new positions and adding to 26 existing holdings. Its largest new stake was AstraZeneca: 1,150,000 shares worth $115M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 80% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Biohaven Pharmaceutical Holding Company Ltd., an estimated $67.1M trimmed.

  • Avidity Partners Management's largest Q4 2020 buy was AstraZeneca: 1,150,000 shares worth $115M.
  • Avidity Partners Management added most to Avantor in Q4 2020, an estimated $51.7M increase.
  • Avidity Partners Management's biggest Q4 2020 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $67.1M.
  • Avidity Partners Management fully exited Seagen Inc. Common Stock in Q4 2020, selling an estimated $104M.
  • Avidity Partners Management's ten largest holdings make up 38% of its $3.08B portfolio in Q4 2020.
  • Avidity Partners Management opened 53 new positions and closed 25 in Q4 2020.
  • Avidity Partners Management's portfolio value rose 43% quarter-over-quarter to $3.08B.

Based on Avidity Partners Management's 13F filing for Q4 2020, filed 16 Feb 2021.